Please login to the form below

Not currently logged in
Email:
Password:

NTDT

This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical

Latest news

  • CHMP backs Novartis' Bexsero, Exjade CHMP backs Novartis' Bexsero, Exjade

    It was approved in Europe in March, 2010. Thalassaemia candidate. Meanwhile, the CHMP also gave its backing to Novartis' Exjade (deferasirox) as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, ... Clinical trials have shown

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics